Radiation may buy time for liver cancer patients before stronger meds needed

NCT ID NCT06261047

Completed Disease control Sponsor: Shandong Cancer Hospital and Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving radiotherapy to liver cancer patients with limited tumor growth (oligo progression) could delay the need for second-line drug therapy. Thirty-six adults with advanced hepatocellular carcinoma received targeted radiation. The goal was to see if this approach could extend progression-free survival and improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiotherapy
What this could lead to: If successful, this approach could help liver cancer patients delay starting second-line drug therapy, potentially improving quality of life and extending time without disease progression.
What could go wrong: This is a small, single-arm Phase II trial with only 36 participants, so results may not apply broadly. Radiotherapy also carries risks like fatigue, skin irritation, or damage to nearby organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA RADIOTHERAPY

Contacts and locations

Locations

Jinbo Yue

Jinan, Shandong, 250000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.